Array BioPharma Inc. (ARRY)
F4Q2012 Earnings Conference Call
August 14, 2012, 09:00 a.m. ET
Tricia Haugeto - IR
Ron Squarer - CEO
Mike Carruthers - CFO
Kevin Koch - President and CSO
David Snitman - COO and VP, Business Development
Karsten Witt - VP, Clinical Sciences
Eun Yang - Jefferies and Company
Jim Birchenough - BMO Capital Markets
Matt Lowe - JP Morgan
Mike King - Rodman & Renshaw
Ed Tenthoff - Piper Jaffray
Good day ladies and gentlemen and welcome to Q4 2012 Array BioPharma, Inc. Conference Call. My name is [Cheverly] and I will be your operator for today. At this time all participants are in listen-only mode. Late we will conduct the question-and-answer session. (Operator Instructions)
I’d now like to turn the conference over to your host for today Ms. Tricia Haugeto from Array BioPharma. Please proceed.
Thank you, [Cheverly], good morning and welcome once again to Array BioPharma’s conference call to discuss our financial results for the fourth quarter and full-year of fiscal 2012. You can listen to this conference call is Array’s website at www.ArrayBioPharma.com. Also we are using slide today to accompany our remarks. These slides can be downloaded on the Investor Relations home page of our website. In addition a replay of the conference call will be available as a webcast from our website.
I’d like to introduce Array’s Chief Executive Officer, Ron Squarer; and our Chief Financial Officer, Mike Carruthers who will lead the call today. I’d also like to introduce Kevin Koch, our President and Chief Scientific Officer who will provide a summary of recent clinical trial results as well as David Snitman, our Chief Operating Officer and Vice President of Business Development; and Karsten Witt, our Vice President of Clinical Sciences who will be available to answers question as needed.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts